Flumazenil is a specific benzodiazepine (BZD) antagonist which inhibits the effects of BZD agonists by competing for the receptor site in the central nervous system. It has completed clinical trials in the United States and received final approval from the U.S. Food and Drug Administration for release in January 1992. Following intravenous injection, clinically apparent arousal usually occurs w...

The withdrawal syndrome from benzodiazepine (BZD) can be severe and in some cases may impede cessation of the use of the drug. We present here a case series of benzodiazepine detoxification by flumazenil infusion, stabilised with clonazepam. Patients were treated with flumazenil 1.35 mg/day for a median of 7 days. Self-reported physical withdrawal symptoms were recorded daily. In addition to fl...

OBJECTIVE To determine how benzodiazepine (BZD) sensitivity testing might be utilized to choose potentially useful antiepileptic drugs. METHODS A retrospective audit of BZD sensitivity testing was carried out on 76 difficult pediatric epileptic cases that attended the Pediatric Neurology services at The Royal Hospital for Sick Children Edinburgh, Scotland from February 2005 to February 2006. ...

Benzodiazepines (BZDs) are widely used in clinical practice as anxiolytics, hypnotics, anticonvulsants and muscle relaxants. However, they have some undesired effects including memory problems. In continuing our research on novel benzodiazepine ligands, we are looking for ligands with less adverse effects. Previously, 4 novel derivatives of 2-phenoxy phenyl-1,3,4-oxadiazole were synthesized as ...

AIMS To evaluate the homogeneity of the elements of the Substance Dependence Syndrome (SDS) as applied to benzodiazepines (BZDs) by Rasch modelling. MEASUREMENTS The Rasch scaling model was applied to data obtained by administering the SCAN (Schedules for Clinical Assessments in Neuropsychiatry) substance dependence sections. Subsequently, Rasch-homogeneous sets of DSM-III-R and ICD-10 BZD de...

The aim of this study was to identify risk factors for benzodiazepine (BZD) dependence, such as sociodemographic variables, characteristics of BZD use, and psychiatric parameters, which to date have been found to relate inconsistently to indicators of BZD dependence such as chronic BZD use and BZD withdrawal symptoms. The Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ), Schedul...

Despite the fact that there have been many reports on benzodiazepine (BZD) dependence, consensus about its definition has not been reached. Reliable prevalence data to estimate the dependence liability of BZDs are therefore lacking. This study is the first to assess the prevalence of BZD dependence in out-patient BZD users (115-general practice (GP) patients, 124 psychiatric out-patients and 33...

Introduction Benzodiazepines (BZDs) have a broad spectrum of therapeutic effects, with undeniable efficacy and low toxicity/lethality. The high prevalence anxiety sleep disorders makes them one the most prescribed drugs in world. We chosen to focus on these because interest they arouse nowadays due potential danger linked their prolonged or abusive use, which can major consequences state health...

Enzymatic disproportionation of cyclohex-2-enone was screened using Agilent J&W GC columns. Published by Elsevier B. V. Essential oils of six Juniperus taxa indigenous in Greece Parasitology Research, 110, 1829-1839 (2012) Tags F. Vourlioti-Arapi et al. HP-5ms, 7890A GC, 5957C MSD, clinical research, disease research Abstract Juniper essential oils were analyzed on an Agilent J&W HP-5ms column ...

benzodiazepines (bzds) are widely used in clinical practice as anxiolytics, hypnotics, anticonvulsants, and muscle relaxants. however, they have some undesired effects including memory problems. in continuing our research on novel benzodiazepine ligands, we are looking for ligands with less adverse effects. previously, 4 novel derivatives of 2-phenoxy phenyl-1,3,4-oxadiazole were synthesized as...